339 related articles for article (PubMed ID: 15800820)
1. [Comparison of different stool tests for the detection of cancer of the colon].
Vogel T; Driemel C; Hauser A; Hansmann A; Lange S; Jonas M; Möslein G
Dtsch Med Wochenschr; 2005 Apr; 130(14):872-7. PubMed ID: 15800820
[TBL] [Abstract][Full Text] [Related]
2. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
[TBL] [Abstract][Full Text] [Related]
3. Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms.
Rozen P; Levi Z; Hazazi R; Waked A; Vilkin A; Maoz E; Birkenfeld S; Niv Y
Aliment Pharmacol Ther; 2009 Feb; 29(4):450-7. PubMed ID: 19035980
[TBL] [Abstract][Full Text] [Related]
4. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population.
Graser A; Stieber P; Nagel D; Schäfer C; Horst D; Becker CR; Nikolaou K; Lottes A; Geisbüsch S; Kramer H; Wagner AC; Diepolder H; Schirra J; Roth HJ; Seidel D; Göke B; Reiser MF; Kolligs FT
Gut; 2009 Feb; 58(2):241-8. PubMed ID: 18852257
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study.
Hoepffner N; Shastri YM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein J
Aliment Pharmacol Ther; 2006 Jan; 23(1):145-54. PubMed ID: 16393292
[TBL] [Abstract][Full Text] [Related]
6. Validity of new immunological human fecal hemoglobin and albumin tests in detecting colorectal neoplasms--an endoscopy-controlled study.
Sieg A; Scheida M; John MR; Hertel A; Schröter M; Lüthgens K; Schmidt-Gayk H
Z Gastroenterol; 1998 Jun; 36(6):485-90. PubMed ID: 9675833
[TBL] [Abstract][Full Text] [Related]
7. Stool test for colorectal cancer screening--it's time to move!
Loitsch SM; Shastri Y; Stein J
Clin Lab; 2008; 54(11-12):473-84. PubMed ID: 19216253
[TBL] [Abstract][Full Text] [Related]
8. Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer.
Ewald N; Schaller M; Bayer M; Akinci A; Bretzel RG; Kloer HU; Hardt PD
Anticancer Res; 2007; 27(4A):1949-52. PubMed ID: 17649802
[TBL] [Abstract][Full Text] [Related]
9. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls.
Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
Anticancer Res; 2003; 23(2A):851-3. PubMed ID: 12820312
[TBL] [Abstract][Full Text] [Related]
10. Testing of multiple samples increases the sensitivity of stool decay-accelerating factor test for the detection of colorectal cancer.
Mizuno M; Mizuno M; Iwagaki N; Nasu J; Okazaki H; Yamamoto K; Okada H; Tsuji T; Fujita T; Shiratori Y
Am J Gastroenterol; 2003 Nov; 98(11):2550-5. PubMed ID: 14638362
[TBL] [Abstract][Full Text] [Related]
11. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
[TBL] [Abstract][Full Text] [Related]
12. [Fecal occult blood--does a hemoglobin-specific tests improve the diagnosis of relevant colonic neoplasms?].
Gysi B; Lang C; Affolter H
Schweiz Med Wochenschr; 1991 Jun; 121(26):988-90. PubMed ID: 1862316
[TBL] [Abstract][Full Text] [Related]
13. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
Smith A; Young GP; Cole SR; Bampton P
Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
[TBL] [Abstract][Full Text] [Related]
14. [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data].
Ewald N; Toepler M; Akinci A; Kloer HU; Bretzel RG; Hardt PD
Z Gastroenterol; 2005 Dec; 43(12):1313-7. PubMed ID: 16315127
[TBL] [Abstract][Full Text] [Related]
15. A new immunological test strip device for the rapid, qualitative detection of faecal occult blood.
Trojan J; Povse N; Schröder O; Stein J
Z Gastroenterol; 2002 Nov; 40(11):921-4. PubMed ID: 12436369
[TBL] [Abstract][Full Text] [Related]
16. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test.
Levi Z; Hazazi R; Rozen P; Vilkin A; Waked A; Niv Y
Aliment Pharmacol Ther; 2006 May; 23(9):1359-64. PubMed ID: 16629942
[TBL] [Abstract][Full Text] [Related]
17. Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed.
Rozen P; Levi Z; Hazazi R; Waked A; Vilkin A; Maoz E; Birkenfeld S; Leshno M; Niv Y
Aliment Pharmacol Ther; 2009 Apr; 29(8):906-17. PubMed ID: 19183147
[TBL] [Abstract][Full Text] [Related]
18. New stool screening tests for colorectal cancer.
Young GP; Cole S
Digestion; 2007; 76(1):26-33. PubMed ID: 17947816
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy.
Sobhani I; Alzahouri K; Ghout I; Charles DJ; Durand-Zaleski I
Dis Colon Rectum; 2011 Jul; 54(7):876-86. PubMed ID: 21654256
[TBL] [Abstract][Full Text] [Related]
20. Colon cancer screening strategies.
Agrawal J; Syngal S
Curr Opin Gastroenterol; 2005 Jan; 21(1):59-63. PubMed ID: 15687886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
